Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

0.75USD
17 Feb 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.75
Open
$0.73
Day's High
$0.75
Day's Low
$0.73
Volume
266,908
Avg. Vol
222,665
52-wk High
$49.80
52-wk Low
$0.72

GALE.OQ

Chart for GALE.OQ

About

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S),... (more)

Overall

Beta: 2.06
Market Cap(Mil.): $24.14
Shares Outstanding(Mil.): 32.19
Dividend: --
Yield (%): --

Financials

  GALE.OQ Industry Sector
P/E (TTM): -- 28.47 29.39
EPS (TTM): -2.32 -- --
ROI: -52.64 13.57 13.06
ROE: -70.89 14.45 14.19

BRIEF-CVI Investments reports 9.3 pct passive stake in Galena Biopharma

* CVI Investmentsreports 9.3 percent passive stake in Galena Biopharma Inc as of feb 8 - SEC filing Source text for Eikon: Further company coverage:

Feb 17 2017

BRIEF-Galena Biopharma announces pricing of public offering of common stock and warrants

* Galena Biopharma announces pricing of public offering of common stock and warrants

Feb 08 2017

BRIEF-Galena Biopharma announces proposed public offering of common stock and warrants

* Galena Biopharma announces proposed public offering of common stock and warrants Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-RXI Pharmaceuticals names Kiessling to scientific advisory board

* RXI Pharmaceuticals appoints leading oncology expert, Rolf Kiessling, to scientific advisory board Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-Galena biopharma reports positive outcome from the data safety monitoring board on the two Neuvax trials

* Galena Biopharma reports positive outcome from the data safety monitoring board on the two neuvax (nelipepimut-s) clinical trials in combination with trastuzumab

Feb 06 2017

BRIEF-Galena biopharma announces the resignation of its President and CEO and the evaluation of strategic alternatives

* Galena Biopharma announces the resignation of its President and Chief Executive Officer and the evaluation of strategic alternatives

Jan 31 2017

BRIEF-RXi Pharmaceuticals CEO Cauwenbergh buys 10,000 shares of co's common stock on Jan 19

* RXi Pharmaceuticals Corp CEO Geert Cauwenbergh reports purchase of 10,000 shares of co's common stock on Jan 19 - SEC filing Source text: (http://bit.ly/2iGe8Re) Further company coverage:

Jan 19 2017

BRIEF-Opko Health reports 5.11 pct Passive Stake in Rxi Pharmaceuticals

* Opko Health reports 5.11 pct passive stake in RXi Pharmaceuticals Corp as of Dec 21, 2016 - SEC filing Source text: (http://bit.ly/2jJqgB2) Further company coverage:

Jan 12 2017

BRIEF-RXi Pharmaceuticals reports Q3 financial results

* RXi Pharmaceuticals Corp - Net loss for quarter ended september 30, 2016 was $2.2 million, compared with $2.5 million for quarter ended September 30, 2015

Nov 10 2016

BRIEF-Galena Biopharma Q3 loss per share $0.03

* Galena biopharma reports third quarter 2016 financial results and provides a corporate update

Nov 09 2016

More From Around the Web

Earnings vs. Estimates